Related Experiment Video

Updated: Jun 21, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Imatinib mesylate causes growth plate closure in vivo

K Vandyke, A L Dewar, S Fitter

    Leukemia
    |July 24, 2009
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
    10:49

    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

    Published on: September 18, 2013

    Related Experiment Videos

    Last Updated: Jun 21, 2026

    Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
    06:00

    Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

    Published on: May 14, 2016

    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
    10:49

    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

    Published on: September 18, 2013

    Related Concept Videos

    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

    Articles linked to this work by shared authors, journal, and citation graph.

    Myeloma bone disease: A constant problem in the changing landscape of myeloma management.

    British journal of haematology·2025

    European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

    Leukemia·2020

    Increasing thermal stress for tropical coral reefs: 1871-2017.

    Scientific reports·2018

    Large-scale bleaching of corals on the Great Barrier Reef.

    Ecology·2017

    A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.

    Leukemia·2017

    Histone deacetylases (HDAC) in physiological and pathological bone remodelling.

    Bone·2016

    Csnk1a1 E98 mutations rewire signaling and metabolism in del(5q) myelodysplastic neoplasms.

    Leukemia·2026

    Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy.

    Leukemia·2026

    KLF4/MLL3 complex axis drives NRBP2 transcription to eliminate acute myeloid leukemia cells.

    Leukemia·2026

    Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.

    Leukemia·2026

    Incidence, prevalence, and survival outcomes of patients with myeloproliferative neoplasms in the United States: a Surveillance, Epidemiology, and End Results (SEER) database analysis, years 2000-2021.

    Leukemia·2026

    Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome.

    Leukemia·2026

    Deficiency of GLUT1 in macrophages reprograms tumor-associated macrophages to normalize tumor vasculature and retards the progression of tumors.

    International journal of biological sciences·2026

    A proposal of good manufacturing practices (GMP) laboratory for CAR T-cell therapy in Latin America and the Caribbean: challenges and opportunities.

    Frontiers in public health·2026

    In vivo selection of anti-glioblastoma DNA aptamer-drug conjugates in an orthotopic patient-derived xenograft model.

    NAR cancer·2026

    From static risk to dynamic disease monitoring: the role of MRD and immune profiling in multiple myeloma.

    Frontiers in immunology·2026

    Doravirine and islatravir for HIV-1 treatment: A systematic review and meta-analysis with GRADE assessment.

    Therapeutic advances in infectious disease·2026

    Advancement in Inflammation-responsive Drug Delivery System for Chronic Inflammation.

    Anti-inflammatory & anti-allergy agents in medicinal chemistry·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us